Chris Hindley

Chris Hindley has extensive work experience in the field of scientific research. Starting in 2011, they worked as a Postdoctoral Researcher at Albert-Ludwigs-Universität Freiburg im Breisgau, where they focused on investigating the role of Hippo signaling during human neural development using human neural stem cells derived from pluripotent cells. In 2014, they joined the University of Cambridge as a Postdoctoral Researcher until 2016. During this time, they conducted further research in the field. From 2016 to 2022, Chris worked at Astex Pharmaceuticals (UK), initially as a Research Associate and then as a Senior Research Associate. Chris'sresponsibilities involved contributing to various research projects. Currently, they are employed at Adrestia Therapeutics as a Principal Scientist, a role they started in 2022.

Chris Hindley completed their education with a Bachelor of Biochemistry from the University of Oxford, where they attended from 2003 to 2007. Following this, they pursued a PhD in Neural development and cell cycle at the University of Cambridge, from 2007 to 2011.